Understanding the effects of novel cancer drugs on the tumor microenvironment will be crucial for their successful use in patients. In this issue of Cancer Research, Ghosh and colleagues discuss the effect of two promising heme-targeting agents on the vascular network in mouse models of lung cancer, utilizing emerging optoacoustic imaging approaches. The findings demonstrating significant, dynamic modulation of tumor hypoxia with the heme-targeting drug treatments create important opportunities for image-guided combination therapy.
